Since the start of the COVID-19 pandemic, 10-30% of the general population have experienced some sort of virus-induced cognitive impairment, including impaired concentration, brain confusion, memory...
In a clinical trial conducted by researchers at the Stanford University School of Medicine, a 15-day course of paxlobriand, a combination of antiviral drugs targeting SARS-CoV-2,...
Recent Comments